Renaissance of an “old” vaccine

In 2014, the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed a new routine vaccination schedule to optimise poliomyelitis prevention after the switch from trivalent to bivalent types 1 and 3 OPV (bOPV).10 This schedule calls for one dose of IPV after multiple doses of bOPV, to mi...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2016-03, Vol.16 (3), p.268-270
Main Authors: Sutter, Roland W, Kew, Olen M
Format: Article
Language:English
Subjects:
Female
Humans
Immunization
Infectious Disease
Infectious diseases
Licenses
Male
Poliomyelitis
Poliomyelitis - prevention & control
Poliovirus - immunology
Poliovirus Vaccine, Inactivated - adverse effects
Poliovirus Vaccine, Inactivated - immunology
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c466t-4affac074a2511ba36f1b047a90e2d25d76676ba6df0110d0b12a7a7cab23daf3
container_end_page 270
container_issue 3
container_start_page 268
container_title The Lancet infectious diseases
container_volume 16
creator Sutter, Roland W
Kew, Olen M
description In 2014, the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed a new routine vaccination schedule to optimise poliomyelitis prevention after the switch from trivalent to bivalent types 1 and 3 OPV (bOPV).10 This schedule calls for one dose of IPV after multiple doses of bOPV, to mitigate the paralytic consequences of circulating vaccine-derived poliovirus type 2 after the switch, and close the remaining immunity gaps to poliovirus types 1 and 3. When countries use only IPV, no new circulating vaccine-derived polioviruses, vaccine-associated paralytic poliomyelitis, or prolonged excretion of poliovirus in immunodeficient individuals will be generated, and IPV will contribute to secure the final eradication of poliomyelitis.
doi_str_mv 10.1016/S1473-3099(15)00526-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1768614314</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309915005265</els_id><sourcerecordid>3966560401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-4affac074a2511ba36f1b047a90e2d25d76676ba6df0110d0b12a7a7cab23daf3</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMotlYfQSl0o4vRc2ZycTaKFG8gCF7W4UySgdR2pk7aQnd9EH25PonTTlVwIwQSwn--w_8xdohwioDy7Bm5SqIE0vQYxQmAiGUktli7_uYR50Jtr99NpMX2QhgAoELgu6wVS4UpiLTNek-uIB8CFcZ1y7xLRXe5-CiHdrn47M7IGF-4fbaT0zC4g83dYa831y_9u-jh8fa-f_UQGS7lJOKU52RAcYoFYkaJzDEDrigFF9tYWCWlkhlJmwMiWMgwJkXKUBYnlvKkw3oNd1yV71MXJnpQTquiXqlRyXOJPKlPh4kmZaoyhMrlelz5EVVzjaBXavRajV711ij0Wo0W9dzRhj7NRs7-TH27qAOXTcDVHWfeVToY72ov1lfOTLQt_b8rLv4QzNAX3tDwzc1d-G2jQ6yhgawYKNYEkXwBzGCHjA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1768614314</pqid></control><display><type>article</type><title>Renaissance of an “old” vaccine</title><source>ScienceDirect Freedom Collection</source><creator>Sutter, Roland W ; Kew, Olen M</creator><creatorcontrib>Sutter, Roland W ; Kew, Olen M</creatorcontrib><description>In 2014, the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed a new routine vaccination schedule to optimise poliomyelitis prevention after the switch from trivalent to bivalent types 1 and 3 OPV (bOPV).10 This schedule calls for one dose of IPV after multiple doses of bOPV, to mitigate the paralytic consequences of circulating vaccine-derived poliovirus type 2 after the switch, and close the remaining immunity gaps to poliovirus types 1 and 3. When countries use only IPV, no new circulating vaccine-derived polioviruses, vaccine-associated paralytic poliomyelitis, or prolonged excretion of poliovirus in immunodeficient individuals will be generated, and IPV will contribute to secure the final eradication of poliomyelitis.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(15)00526-5</identifier><identifier>PMID: 26719059</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Female ; Humans ; Immunization ; Infectious Disease ; Infectious diseases ; Licenses ; Male ; Poliomyelitis ; Poliomyelitis - prevention &amp; control ; Poliovirus - immunology ; Poliovirus Vaccine, Inactivated - adverse effects ; Poliovirus Vaccine, Inactivated - immunology ; Vaccines</subject><ispartof>The Lancet infectious diseases, 2016-03, Vol.16 (3), p.268-270</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Mar 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c466t-4affac074a2511ba36f1b047a90e2d25d76676ba6df0110d0b12a7a7cab23daf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26719059$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sutter, Roland W</creatorcontrib><creatorcontrib>Kew, Olen M</creatorcontrib><title>Renaissance of an “old” vaccine</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>In 2014, the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed a new routine vaccination schedule to optimise poliomyelitis prevention after the switch from trivalent to bivalent types 1 and 3 OPV (bOPV).10 This schedule calls for one dose of IPV after multiple doses of bOPV, to mitigate the paralytic consequences of circulating vaccine-derived poliovirus type 2 after the switch, and close the remaining immunity gaps to poliovirus types 1 and 3. When countries use only IPV, no new circulating vaccine-derived polioviruses, vaccine-associated paralytic poliomyelitis, or prolonged excretion of poliovirus in immunodeficient individuals will be generated, and IPV will contribute to secure the final eradication of poliomyelitis.</description><subject>Female</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Licenses</subject><subject>Male</subject><subject>Poliomyelitis</subject><subject>Poliomyelitis - prevention &amp; control</subject><subject>Poliovirus - immunology</subject><subject>Poliovirus Vaccine, Inactivated - adverse effects</subject><subject>Poliovirus Vaccine, Inactivated - immunology</subject><subject>Vaccines</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUhoMotlYfQSl0o4vRc2ZycTaKFG8gCF7W4UySgdR2pk7aQnd9EH25PonTTlVwIwQSwn--w_8xdohwioDy7Bm5SqIE0vQYxQmAiGUktli7_uYR50Jtr99NpMX2QhgAoELgu6wVS4UpiLTNek-uIB8CFcZ1y7xLRXe5-CiHdrn47M7IGF-4fbaT0zC4g83dYa831y_9u-jh8fa-f_UQGS7lJOKU52RAcYoFYkaJzDEDrigFF9tYWCWlkhlJmwMiWMgwJkXKUBYnlvKkw3oNd1yV71MXJnpQTquiXqlRyXOJPKlPh4kmZaoyhMrlelz5EVVzjaBXavRajV711ij0Wo0W9dzRhj7NRs7-TH27qAOXTcDVHWfeVToY72ov1lfOTLQt_b8rLv4QzNAX3tDwzc1d-G2jQ6yhgawYKNYEkXwBzGCHjA</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Sutter, Roland W</creator><creator>Kew, Olen M</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20160301</creationdate><title>Renaissance of an “old” vaccine</title><author>Sutter, Roland W ; Kew, Olen M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-4affac074a2511ba36f1b047a90e2d25d76676ba6df0110d0b12a7a7cab23daf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Female</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Licenses</topic><topic>Male</topic><topic>Poliomyelitis</topic><topic>Poliomyelitis - prevention &amp; control</topic><topic>Poliovirus - immunology</topic><topic>Poliovirus Vaccine, Inactivated - adverse effects</topic><topic>Poliovirus Vaccine, Inactivated - immunology</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sutter, Roland W</creatorcontrib><creatorcontrib>Kew, Olen M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sutter, Roland W</au><au>Kew, Olen M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renaissance of an “old” vaccine</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>16</volume><issue>3</issue><spage>268</spage><epage>270</epage><pages>268-270</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>In 2014, the Strategic Advisory Group of Experts (SAGE) on Immunization endorsed a new routine vaccination schedule to optimise poliomyelitis prevention after the switch from trivalent to bivalent types 1 and 3 OPV (bOPV).10 This schedule calls for one dose of IPV after multiple doses of bOPV, to mitigate the paralytic consequences of circulating vaccine-derived poliovirus type 2 after the switch, and close the remaining immunity gaps to poliovirus types 1 and 3. When countries use only IPV, no new circulating vaccine-derived polioviruses, vaccine-associated paralytic poliomyelitis, or prolonged excretion of poliovirus in immunodeficient individuals will be generated, and IPV will contribute to secure the final eradication of poliomyelitis.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>26719059</pmid><doi>10.1016/S1473-3099(15)00526-5</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1473-3099
ispartof The Lancet infectious diseases, 2016-03, Vol.16 (3), p.268-270
issn 1473-3099
1474-4457
language eng
recordid cdi_proquest_journals_1768614314
source ScienceDirect Freedom Collection
subjects Female
Humans
Immunization
Infectious Disease
Infectious diseases
Licenses
Male
Poliomyelitis
Poliomyelitis - prevention & control
Poliovirus - immunology
Poliovirus Vaccine, Inactivated - adverse effects
Poliovirus Vaccine, Inactivated - immunology
Vaccines
title Renaissance of an “old” vaccine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A05%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renaissance%20of%20an%20%E2%80%9Cold%E2%80%9D%20vaccine&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Sutter,%20Roland%20W&rft.date=2016-03-01&rft.volume=16&rft.issue=3&rft.spage=268&rft.epage=270&rft.pages=268-270&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(15)00526-5&rft_dat=%3Cproquest_cross%3E3966560401%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c466t-4affac074a2511ba36f1b047a90e2d25d76676ba6df0110d0b12a7a7cab23daf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1768614314&rft_id=info:pmid/26719059&rfr_iscdi=true